Survey Examining the Frequency and Severity of Acid Related Symptoms While Taking Nexium

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

491 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-05-31

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the effectiveness of Nexium at alleviating upper GI symptoms in subjects and evaluate with which treatment regimen and on which indications acid suppression with isomeric proton pump inhibitor is used in routine clinical practice in Albania.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Drug Interaction Study Between AZD3355 and Nexium

NCT00684190

Gastroesophageal Reflux Disease

COMPLETED PHASE1

Chest Pain Pilot Study

NCT00251901

Chest Pain Gastroesophageal Reflux

COMPLETED PHASE3

Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD

NCT00295685

GERD

COMPLETED PHASE4

Study of Acid Reflux in Asthma

NCT00069823

Asthma Lung Diseases Lung Diseases, Obstructive

COMPLETED PHASE3

Nexium Capsules RE Maintenance Specific Clinical Experience Investigation

NCT01562639

Repeatedly Recurring Esophagitis Relapsing Reflux Esophagitis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Acid Suppression Proton Pump Inhibitors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject must have had upper GI symptoms requiring acid suppression treatment
* Treatment with Nexium is in accordance with indications and dosing approved in Albania.
* Start of treatment at least 2 weeks prior to enrollment to this study 5. Written informed consent is signed.

Exclusion Criteria

* Known hypersensitivity to Nexium or any other constituents of the formulation
* Concomitant administration of atazanavir and nelfinavir.
* Alarming upper GI symptoms (i.e. significant unintended weight loss, vomiting, dysphasia, hematemesis, melena, fever, jaundice or any other sign indicating serious or malignant disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No